ClinicalTrials.gg
CompletedNCT03143413Updated Nov 17, 2026

Echo Systemic Sclerosis

An observational study in Systemic Sclerosis, Gougerot Sjogren Syndrome and Sicca-Asthenia-Polyalgia Syndrome, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 17, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
108
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.

Enrollment
30th of 50
108 · median 150
Started
2017
with 3 others
Observational
51 of 132
17 open now
Registered
43rd of 132
by date

Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 30th largest by enrollment of the 50 observational ones that give a count, is one of 4 that started in 2017, is one of 51 observational ones, and was the 43rd registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Scleroderma, Systemic with a site in France, or all of them as a file.
02

Study summary

Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis. Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia). It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other). Several criteria have been validated to classify the SS but require a labial salivary gland biopsy, invasive act which complications can sometimes be reported (hematoma, lip sensory defect).

Several scores based on the evaluation of the ultrasound homogeneity of the salivary glands were developed but no studies have evaluated ultrasound abnormalities of salivary glands in patients with systemic sclerosis.

Read the detailed description

Descriptive explorative study of three population showing sicca symptoms (Systemic sclerosis, Gougerot-Sjogren syndrome, Sicca-Asthenia-Polyalgia syndrome).

Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).

Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.

03

Conditions studied

  • Systemic Sclerosis
  • Gougerot Sjogren Syndrome
  • Sicca-Asthenia-Polyalgia Syndrome

Keywords

  • Salivary glands ultrasonography
  • Systemic sclerosis
  • Gougerot Sjogren syndrome
  • Sicca syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

20 systemic sclerosis, 40 Gougerot-Sjogren syndrome, 40 Sicca-Asthenia-Polyalgia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systemic sclerosis diagnosis established by a rheumatologist and met ACR 2012 criteria
  • Or primary Gougerot-Sjogren patient who met American-European Consensus Group (AECG) classification criteria.
  • Or patient presenting a sicca syndrome but not met Gougerot-Sjogren criteria

Exclusion criteria

Exclusion Criteria:

  • History of radiotherapy on face and neck
  • Infection such as VIH or
  • Sarcoidosis
  • Amylosis
  • Wearing contact lenses
  • Hyper IgG4 syndrome
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
108 participants (actual)
Patient registry
No

Groups and cohorts

  • Systemic sclerosis

    Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.

    Other: Ultrasonography

  • Gougerot-Sjogren syndrome

    Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).

    Other: Ultrasonography

  • Sicca-Asthenia-Polyalgia syndrome

    It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).

    Other: Ultrasonography

Interventions

  • OtherUltrasonography

    Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France). Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.

06

What researchers measure

Primary outcomes

  1. Jousse-Joulin ultrasonography score

    Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.

    Time frame: the day of inclusion

Secondary outcomes

  1. Ultrasonography score equal or higher than 2 on at least one salivary gland

    Time frame: the day of inclusion

  2. Ultrasonography score equal or higher than 3 on at least one salivary gland

    Time frame: the day of inclusion

  3. Global ultrasonography score higher than 6/16

    Time frame: the day of inclusion

  4. Salivary glands area

    Time frame: the day of inclusion

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, Auvergne 63003, France
08

References and documents

Publications

  • Couderc M, Tournadre A, Mathieu S, Pereira B, Soubrier M, Dubost JJ. Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjogren's syndrome? Ann Rheum Dis. 2020 Oct;79(10):e137. doi: 10.1136/annrheumdis-2019-215777. Epub 2019 Jun 12. No abstract available. PubMed 31189553 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Dec 2018, 21 months.

Of 59 non-industry observational studies under Scleroderma, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 80. This study's 21 months is below that.

Counting every sponsor, half of 61 studies reached it within 44 months; a quarter within 17 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Mar 2019 → Dec 2018 and completion May 2019 → Feb 2019.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2017
First posted
May 8, 2017
StartActual
Mar 24, 2017
Primary completionActual
Dec 31, 2018was Mar 2019
CompletionActual
Feb 28, 2019was May 2019
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Primary completion
Mar 2019→Dec 31, 2018 (actual)
Nov 17, 2026
Study completion
May 2019→Feb 28, 2019 (actual)
Nov 17, 2026
Enrollment
100 (estimated)→108 (actual)
Nov 17, 2026
Publications
Results publication added: Couderc M, Tournadre A, Mathieu S, Pereira B, Soubrier M, Dubost JJ. Do the salivary glands of patients with systemic sclerosis show ultrasonographic modificat… PubMed 31189553 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Couderc M, Tournadre A, Mathieu S, Pereira B, Soubrier M, Dubost JJ. Do the salivary glands of patients with systemic sclerosis show ultrasonographic modificat… PubMed 31189553 ↗
    Primary completion Mar 2019→Dec 31, 2018 (now actual)
    Study completion May 2019→Feb 28, 2019 (now actual)
    Enrollment 100 (estimated)→108 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03143413
Responsible party
Sponsor
First posted
May 8, 2017
Start date
Mar 24, 2017
Primary completion
Dec 31, 2018
Completion
Feb 28, 2019
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion